Profile data is unavailable for this security.
About the company
BenevolentAI SA is an artificial intelligence (AI)-enabled drug discovery and development company. Through the combined capabilities of this AI platform, its scientific expertise, and wet-lab facilities, it delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers its in-house drug pipeline and supports collaborations with AstraZeneca, as well as research and charitable institutions. Its pipeline includes BEN-2293, BEN-8744, BEN-9160 and BEN-28010. It integrates data from across domains and data types, including omics, molecules, experiments, literature, pathology and biological systems to provide a holistic view of biology. BEN-8744 is under development as an ulcerative colitis treatment for a novel target discovered using its AI platform. BEN-2293 is a topical PanTrk inhibitor in development to relieve inflammation and rapidly resolve itch in patients with atopic dermatitis.
- Revenue in EUR (TTM)8.55m
- Net income in EUR-73.83m
- Incorporated2021
- Employees248.00
- LocationBenevolentAI SA4-8 Maple StreetLONDON W1T 5HDUnited KingdomGBR
- Websitehttps://www.benevolent.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Celadon Pharmaceuticals PLC | 24.18k | -9.40m | 75.99m | -- | -- | 20.79 | -- | 3,142.34 | -0.1306 | -0.1306 | 0.0003 | 0.0488 | 0.0016 | 267.85 | 0.0248 | -- | -64.68 | -- | -71.16 | -- | -29,080.42 | -- | -40,384.18 | -- | 1.84 | -12.45 | 0.6052 | -- | -- | -- | -- | -- | -- | -- |
| Poolbeg Pharma PLC | 0.00 | -4.58m | 77.83m | 12.00 | -- | 4.62 | -- | -- | -0.0079 | -0.0079 | 0.00 | 0.0289 | 0.00 | -- | -- | -- | -22.65 | -- | -24.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 16.11 | -- | -- | -- |
| Captor Therapeutics SA | 3.05m | -16.32m | 80.98m | 104.00 | -- | 5.57 | -- | 26.54 | -16.42 | -16.42 | 3.04 | 14.90 | 0.1256 | -- | 3.59 | 126,932.70 | -67.13 | -- | -82.96 | -- | 52.28 | -- | -534.69 | -- | -- | -- | 0.0518 | -- | 44.15 | -- | -96.65 | -- | -- | -- |
| BenevolentAI SA | 8.55m | -73.83m | 87.68m | 248.00 | -- | 0.682 | -- | 10.26 | -0.6266 | -0.6266 | 0.0725 | 0.9014 | 0.0473 | -- | 0.3631 | 34,468.13 | -40.88 | -- | -48.87 | -- | -- | -- | -863.69 | -- | -- | -- | 0.048 | -- | -30.58 | -- | 61.38 | -- | -- | -- |
| Vistin Pharma ASA | 37.43m | 4.80m | 88.24m | 77.00 | 18.37 | 3.48 | 13.95 | 2.36 | 1.27 | 1.27 | 9.88 | 6.70 | 1.11 | 2.31 | 7.44 | 5,692,663.00 | 14.28 | 1.73 | 18.93 | 2.11 | 59.93 | 58.92 | 12.83 | 2.36 | 0.8536 | 32.96 | 0.0934 | -- | 51.35 | 16.95 | 1,066.84 | -- | -0.1922 | -- |
| Eco Animal Health Group Plc | 103.15m | -1.89m | 88.87m | 228.00 | -- | 0.9346 | 31.62 | 0.8615 | -0.024 | -0.024 | 1.31 | 1.20 | 0.7664 | 1.92 | 3.41 | 387,986.80 | -0.1949 | 6.03 | -0.2645 | 8.02 | 43.05 | 46.41 | -0.2544 | 7.89 | 2.26 | 1.22 | 0.0437 | 55.72 | 3.79 | 4.89 | 246.94 | -35.90 | -4.43 | -- |
| 4Sc AG | 304.00k | -8.24m | 89.00m | 15.00 | -- | 17.62 | -- | 292.77 | -0.8144 | -0.8144 | 0.0301 | 0.4995 | 0.0236 | -- | 3.68 | 20,266.67 | -63.84 | -39.49 | -77.78 | -42.84 | 68.75 | 92.24 | -2,709.54 | -337.74 | -- | -- | 0.00 | -- | -30.28 | -40.78 | 42.64 | -- | -56.05 | -- |
| Cantourage Group SE | -100.00bn | -100.00bn | 89.06m | 2.00 | -- | 2.01 | -- | -- | -- | -- | -- | 3.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Moberg Pharma AB (publ) | 0.00 | -1.81m | 89.24m | -- | -- | 1.67 | -- | -- | -1.20 | -1.20 | 0.00 | 21.84 | 0.00 | -- | -- | -- | -3.52 | -- | -3.66 | -- | -- | -- | -- | -- | 3.04 | -- | 0.0077 | -- | -100.00 | -- | -34.26 | -- | -- | -- |
| Anatolia TaniveBytklj Unli Ar Ge SiveTiA | 4.71m | 3.52m | 89.85m | 183.00 | 14.96 | 3.84 | 20.74 | 19.09 | 0.9498 | 0.9498 | 0.993 | 3.70 | 0.192 | 0.4361 | 2.38 | 992,388.10 | 14.37 | -- | 14.98 | -- | 71.92 | -- | 74.86 | -- | 10.57 | -- | 0.0206 | -- | -34.45 | -- | -23.76 | -- | -- | -- |
| XSpray Pharma AB (publ) | 0.00 | -15.43m | 90.02m | 26.00 | -- | 1.89 | -- | -- | -7.02 | -7.02 | 0.00 | 22.19 | 0.00 | -- | -- | 0.00 | -26.60 | -18.38 | -28.03 | -19.26 | -- | -- | -- | -- | 4.36 | -- | 0.0504 | -- | -- | -- | -36.45 | -- | 2.87 | -- |
| Haemato AG | 260.81m | 9.61m | 90.99m | 78.00 | 9.45 | 0.6068 | 8.45 | 0.3489 | 1.84 | 1.84 | 50.10 | 28.67 | 1.47 | 9.80 | 12.48 | 3,343,690.00 | 5.41 | 2.01 | 6.45 | 2.70 | 7.56 | 8.42 | 3.68 | 1.21 | 1.66 | -- | 0.0203 | 157.20 | -12.95 | -3.03 | 25.39 | 3.32 | -5.75 | -16.74 |
| Cereno Scientific AB | 0.00 | -4.13m | 91.35m | 5.00 | -- | 4.09 | -- | -- | -0.241 | -0.241 | 0.00 | 0.9258 | 0.00 | -- | -- | 0.00 | -19.22 | -16.81 | -20.75 | -18.26 | -- | -- | -- | -- | -- | -12.92 | 0.1734 | -- | -- | -- | -73.95 | -- | 44.79 | -- |
| Diamyd Medical AB | 24.22k | -10.32m | 97.20m | 26.00 | -- | 5.85 | -- | 4,013.92 | -1.41 | -1.41 | 0.0033 | 1.91 | 0.0014 | -- | 6.56 | 11,280.00 | -59.77 | -25.46 | -66.19 | -28.37 | -4,930.85 | -1,419.23 | -42,617.73 | -5,896.43 | -- | -130.78 | 0.1176 | -- | 20.26 | -5.54 | -12.13 | -- | -- | -- |
| Infant Bacterial Therapeutics AB | 0.00 | -10.57m | 98.82m | 8.00 | -- | 3.90 | -- | -- | -9.90 | -9.90 | 0.00 | 22.65 | 0.00 | -- | -- | 0.00 | -35.11 | -16.11 | -38.65 | -16.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -88.03 | -- | -- | -- |
| Scancell Holdings Plc | 0.00 | -13.20m | 99.01m | 51.00 | -- | -- | -- | -- | -0.0138 | -0.0138 | 0.00 | -0.0102 | 0.00 | -- | -- | 0.00 | -37.31 | -33.32 | -40.52 | -35.82 | -- | -- | -- | -817.98 | -- | -- | 1.73 | -- | -- | -- | -161.24 | -- | 77.85 | -- |
Data as of May 03 2024. Currency figures normalised to BenevolentAI SA's reporting currency: Euro EUR
1.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Mirova SA (Investment Management)as of 29 Feb 2024 | 1.69m | 1.18% |
| DNCA Finance SAas of 30 Jun 2023 | 455.83k | 0.32% |
| Lumyna Investments Ltd.as of 30 Sep 2022 | 0.00 | 0.00% |
Data from 30 Sep 2022 - 24 Apr 2024Source: FactSet Research Systems Inc.
